Amylyx Pharmaceuticals Inc Dossier
Qualitative Analysis
Business overview
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutic options for endocrine conditions and neurodegenerative diseases. Following the strategic withdrawal of its ALS drug Relyvrio/Albrioza (AMX0035) in April 2024, the company has pivoted its primary focus toward its endocrine pipeline. Its lead investigational asset is avexitide, a first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist with FDA Breakthrough Therapy Designation being evaluated for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism. The company is also advancing AMX0114, a clinical-stage antisense oligonucleotide targeting calpain-2 for the treatment of amyotrophic lateral sclerosis (ALS), and AMX0318, a preclinical GLP-1 receptor antagonist in collaboration with Gubra.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead asset avexitide for post-bariatric hypoglycemia (PBH). This includes completing the Phase 3 LUCIDITY trial, initiating a U.S. Expanded Access Program (EAP) for up to 250 adults, drafting sections of the New Drug Application (NDA), and building out commercial capabilities (marketing, market access, and commercial operations) for a potential 2027 launch.
Expected impact: Establishes avexitide as the first FDA-approved therapy for PBH, addressing an unmet need for approximately 160,000 patients in the U.S. and restoring commercial revenue.
Developing AMX0114, an investigational antisense oligonucleotide (ASO) targeting calpain-2, for the potential treatment of amyotrophic lateral sclerosis (ALS). The initiative involves executing the Phase 1 LUMINA multiple ascending dose clinical trial.
Expected impact: Provides clinical proof-of-concept and safety data for a novel neuroprotective mechanism in ALS.
Advancing AMX0318, a novel, long-acting GLP-1 receptor antagonist selected as a development candidate in January 2026 through a collaboration with Gubra A/S, for the treatment of PBH and other rare diseases.
Expected impact: Expands the company's endocrine pipeline with a long-acting therapeutic option, complementing the daily administration profile of avexitide.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquisition of substantially all rights, title, and interests in avexitide out of Eiger's Chapter 11 bankruptcy proceedings. The transaction allowed Amylyx to rebuild its clinical pipeline with a Phase 3-ready asset in hyperinsulinemic hypoglycemia following the market withdrawal of its ALS drug Relyvrio.
Financial impact: Purchased for $35.1 million in cash plus determined cure costs and assumed liabilities, including a 3% royalty on future sales of avexitide in PBH to certain academic institutions.
Strategic Partnerships
Collaborative effort to discover and develop novel, long-acting GLP-1 receptor antagonists using Gubra's AI-driven streaMLine peptide drug discovery platform. This partnership successfully identified and nominated AMX0318 as a development candidate in January 2026.
Terms: Gubra received upfront and research payments, and is eligible to receive more than $50 million in success-based development and commercialization milestones, plus mid-single-digit royalties on worldwide net sales. A $4.0 million milestone payment was recognized by Amylyx in Q1 2026 upon candidate selection and handover.